Sharpton T; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 341 (abstract no. T.B.P.327).
Kaiser Foundation Hospital, Oakland, California, USA
OBJECTIVE: To determine the incidence of polymyositis during Zidovudine (AZT) therapy. METHODS: A 12 month prospective followup of a cohort of 20 patients (pts) taking AZT. Creatine phosphokinase (CPK) was routinely monitored during visits and in pts with symptoms of polymyositis. RESULTS: Eight pts (40%) were found to have elevated CPK over the period of observation. Onset of lab abnormality was from 10 days to 17 months (mean 7.8 months) after starting AZT. Most pts had mild Quadriceps muscle weakness and fatigue on exertion; 1 pt had acute onset Quadriceps tenderness and weakness which resolved in 1 week; 1 pt had chronic weakness limiting ability to ambulate. Myositis either resolved (4 pts) or remained stable (4 pts) despite continued AZT in all patients from 3 to 13 months (mean 4.6) after onset of polymyositis. Peak CPK ranged from 418 to 8941 IU/1 (n1 0-200); duration of elevation varied from 1 to 5 months. No correlation between dose of AZT and severity of polymyositis was found. CONCLUSION: Mild polymyositis is common during Zidovudine therapy but usually resolves or remains stable during continued Zidovudine therapy.
Publication Types:
Keywords:
- Creatine Kinase
- Humans
- Longitudinal Studies
- Muscle, Skeletal
- Muscles
- Myositis
- Polymyositis
- Zidovudine
- therapy
Other ID:
UI: 102177580
From Meeting Abstracts